(Q58158894)

English

Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects

article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

based on heuristic

inferred from title

Tabassome Simon

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

D L Bhatt

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

L Bergougnan

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

C Farenc

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

K Pearson

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

L Perrin

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

E Vicaut

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

F Hurbin

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

M Dubar

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

F Lacreta

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

0 references

publication date

29 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

90

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

287-295

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Cytochrome p-450 polymorphisms and response to clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Genetic determinants of response to clopidogrel and cardiovascular events

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Clopidogrel with or without omeprazole in coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

CYP3A4 and CYP3A5 genotyping by Pyrosequencing

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Resisting the temptation to oversimplify antiplatelet resistance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

A comparison of bayesian methods for haplotype reconstruction from population genotype data

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

A New Statistical Method for Haplotype Reconstruction from Population Data

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

21 January 2018

Impact of P-glycoprotein on clopidogrel absorption

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Paraoxonase-1 is a major determinant of clopidogrel efficacy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CLPT.2011.127

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21716274%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58158894&oldid=1939841838"